Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Dec 2019 Results of a 7.5 year pooled analysis (n=370) of patients with relapsed/refractory Mantle-cell-lymphoma from three trials (SPARK, RAY and PCYC-1104) were presented at the 2019 American Society of Hematology (ASH) Annual Meeting (abstract #1538).
07 Dec 2019 Results of 7.5 year pooled analysis (n=370) from SPARK, RAY and PCYC-1104 trials presented in the AbbVie media release.
06 Nov 2019 Results of updated pooled analysis from four trials (SPARK, RAY, PCYC-1104 and CAN3001) with 15 months (mos) of additional follow-up, and a comparison of outcomes with ibrutinib versus the prior regimen, were released in the 61st Annual Meeting and Exposition of the American Society of Hematology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com